Anti-CCM2 antibody produced in mouse
SIGMA/SAB1400724 - IgG fraction of antiserum, buffered aqueous solution
Synonym: Anti-C7orf22; Anti-MGC4067; Anti-MGC4607; Anti-MGC74868; Anti-PP10187
Product Type: Chemical
Western Blotting CCM2 polyclonal antibody. Western Blot analysis of CCM2 expression in human placenta.
Western Blotting Western Blot analysis of CCM2 expression in transfected 293T cell line by CCM2 polyclonal antibody. Lanes Lane 1: CCM2 transfected lysate (48.84 kDa). Lane 2: Non-transfected lysate.
| antibody form | IgG fraction of antiserum |
| antibody product type | primary antibodies |
| biological source | mouse |
| clone | polyclonal |
| conjugate | unconjugated |
| form | buffered aqueous solution |
| Quality Level | 100  |
| shipped in | dry ice |
| species reactivity | human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | western blot: 1 μg/mL |
| UniProt accession no. | Q9BSQ5  |
| Biochem/physiol Actions: | Cerebral cavernous malformation 2 (CCM2) is associated with several cellular pathways. It mainly behaves as a scaffold protein in the activation of GTPase Rac-dependent p38 mitogen-activated protein kinase (MAPK) during hyperosmotic stress. It also participates in vascular integrity. CCM2 may play a role in vasculogenesis and angiogenesis during the development of the brain. Mutation in the gene is associated with familial cerebral cavernous malformations. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| General description: | Cerebral cavernous malformation 2 (CCM2) is an adaptor protein consisting of two domains. Structurally, it has two domains, N-terminal phosphotyrosine-binding (PTB) domain and an independent domain named as Karet domain at the C-terminal end. It is mapped on human chromosome 7p. Its phosphotyrosine-binding (PTB) domain has the ability to bind proteins. It is expressed in vascular endothelium and neuroglial precursor cells during development and also observed in arterial endothelium, neurons, and some of the glial cells in adult neocortex. |
| Immunogen: | CCM2 (NP_113631.1, 1 a.a. ~ 444 a.a) full-length human protein. Sequence MEEEGKKGKKPGIVSPFKRVFLKGE |
| Physical form: | Solution in phosphate buffered saline, pH 7.4 |
| RIDADR | NONH for all modes of transport |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |